Novel strategies for cancer immunotherapy: counter-immunoediting therapy

Abstract

The advent of immunotherapy has made an indelible mark on the field of cancer therapy, especially the application of immune checkpoint inhibitors in clinical practice. Although immunotherapy has proven its efficacy and safety in some tumors, many patients still have innate or acquired resistance to immunotherapy. The emergence of this phenomenon is closely related to the highly heterogeneous immune microenvironment formed by tumor cells after undergoing cancer immunoediting. The process of cancer immunoediting refers to the cooperative interaction between tumor cells and the immune system that involves three phases: elimination, equilibrium, and escape. During these phases, conflicting interactions between the immune system and tumor cells result in the formation of a complex immune microenvironment, which contributes to the acquisition of different levels of immunotherapy resistance in tumor cells. In this review, we summarize the characteristics of different phases of cancer immunoediting and the corresponding therapeutic tools, and we propose normalized therapeutic strategies based on immunophenotyping. The process of cancer immunoediting is retrograded through targeted interventions in different phases of cancer immunoediting, making immunotherapy in the context of precision therapy the most promising therapy to cure cancer.

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

“…Based on the immune checkpoint blockades associated with the mechanism of action of TIGIT [ 1 , 26 , 66 , 197 ], we summarized a few possible reasons for the failures of early clinical trials in patients with SCLC and NSCLC.…”

Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine

“…It has garnered significant attention as an alternative or complementary treatment to traditional methods like surgery, chemotherapy, and radiotherapy [ 43 ]. Currently, tumor immunotherapy is broadly categorized into two main approaches: active immunotherapy and passive immunotherapy [ 44 ]. DC vaccines are categorized as a form of active immunotherapy, and there are two primary therapeutic approaches.…”

Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

“…However, it is essential to comprehend the influence of aging on how the immune system responds to tumors in order to make informed decisions on the creation and implementation of ICI in elderly individuals. With the introduction of groundbreaking antibodies that modulate the immune system to eliminate tumors, immunosenescence has gained attention in oncology ( 16 – 19 ).…”